Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 5,290 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Leukemia Clear all
Completed No phase listed Observational

Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1

NCT00339638
View directory record Official record
Conditions
Human T-Lymphoma Virus Type I
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

NCT00831766
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
Idarubicin, Cytarabine, Lenalidomide (Revlimid®)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Tampa, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

NCT00492856
View directory record Official record
Conditions
Leukemia
Interventions
mercaptopurine, methotrexate, tretinoin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
210
States / cities
Scottsdale, Arizona • Roseville, California • Sacramento, California + 135 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 29, 2026, 4:31 AM EDT
Terminated Phase 1 Interventional

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

NCT00612612
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Leukemia, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
obatoclax mesylate, fludarabine phosphate, rituximab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

NCT00882102
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine, Gemtuzumab ozogamicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 29, 2026, 4:31 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02225275
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Lenalidomide, Obinutuzumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

NCT00628628
View directory record Official record
Conditions
Tumor Lysis Syndrome
Interventions
As Needed Rasburicase, Fixed Dose Rasburicase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 29, 2026, 4:31 AM EDT
Suspended Phase 2 Interventional

Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

NCT07192237
View directory record Official record
Conditions
Phase 2 Study, Blinatumomab, Acute Lymphoblastic Leukemia
Interventions
Blinatumomab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 29, 2026, 4:31 AM EDT
Withdrawn Phase 1 Interventional

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

NCT04896112
View directory record Official record
Conditions
Acute Myeloid Leukemia, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
Interventions
LNK01002
Drug
Lead sponsor
Lynk Pharmaceuticals Co., Ltd
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Farmington Hills, Michigan • Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 29, 2026, 4:31 AM EDT
Recruiting Not applicable Interventional

Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD)

NCT06956781
View directory record Official record
Conditions
PTSD, Trauma, Pediatric ALL
Interventions
Emotion Regulation, Exposure, Cognitive Processing, Bi-lateral Stimulation, Psychological Placebo
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
8 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Phase 2 Interventional

Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission

NCT00186381
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute, Leukemia, Blood and Marrow Transplant (BMT)
Interventions
high dose chemotherapy then autologous hematopoietic cell transplant
Procedure
Lead sponsor
Stanford University
Other
Eligibility
16 Years to 69 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 29, 2026, 4:31 AM EDT
Active, not recruiting Phase 2 Interventional

Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue

NCT03747757
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Cancer Fatigue, Lymphoma, Secondary Acute Myeloid Leukemia
Interventions
Cognitive Behavior Therapy, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Phase 4 Interventional Results available

Pain Control in Pediatric Oncology: Utility of EMLA Cream vs Lidocaine Injection in Lumbar Punctures

NCT04003012
View directory record Official record
Conditions
Leukemia-Lymphoma
Interventions
EMLA, Lidocaine
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

NCT03406156
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Obinutuzumab, Bendamustine, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
15
States / cities
Tempe, Arizona • Denver, Colorado • Kansas City, Missouri + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 29, 2026, 4:31 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Amish/Mennonite Research Contact Registry

NCT02990572
View directory record Official record
Conditions
All
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Phase 1Phase 2 Interventional

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

NCT04323657
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Interventions
TC-110 T Cells, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
TCR2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Denver, Colorado • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 29, 2026, 4:31 AM EDT
Enrolling by invitation No phase listed Observational

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

NCT05509855
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
Interventions
Genetic: WU-CART-007
Genetic
Lead sponsor
Allotera Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Early Phase 1 Interventional

Nutrition and Physical Activity Intervention in Preventing Excess Weight Gain in Pediatric Patients With Leukemia or Lymphoma Treated With Prednisone and/or Dexamethasone

NCT05049785
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Counseling, Exercise Intervention, Informational Intervention, Nutritional Intervention, Questionnaire Administration
Other · Behavioral · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
7 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 29, 2026, 4:31 AM EDT
Withdrawn Phase 1 Interventional

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

NCT04639843
View directory record Official record
Conditions
Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma, Hepatosplenic T-cell Lymphoma
Interventions
CC-486 (5-azacitidine), Duvelisib, Romidepsin, Doxorubicin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Phase 2 Interventional

Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts

NCT00026858
View directory record Official record
Conditions
Neoplasm
Interventions
collaboration
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 4:31 AM EDT
Recruiting No phase listed Observational

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

NCT05974150
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
Interventions
Web based survey
Other
Lead sponsor
Carevive Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
New Haven, Connecticut • Evanston, Illinois • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

NCT00070135
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Interventions
filgrastim, Anti-Thymocyte Globulin, busulfan, fludarabine phosphate, methotrexate, tacrolimus, Allogeneic Hematopoietic Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
60 Years to 74 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
21
States / cities
San Francisco, California • Lewes, Delaware • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 29, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

NCT01392989
View directory record Official record
Conditions
Neural Tube Defects, Anemia, Leukemia, Myeloid, Bone Marrow Transplant Failure, Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders
Interventions
CIK cells, Cyclosporine, Mycophenolate Mofetil, Thymoglobulin, Total Lymphoid Irradiation (TLI)
Drug · Radiation
Lead sponsor
Everett Meyer
Other
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 29, 2026, 4:31 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients

NCT02137889
View directory record Official record
Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Interventions
VAY736
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 29, 2026, 4:31 AM EDT